Skip to main content
main-content
Top

05-23-2018 | Insulin | Review | Article

Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)

Journal: Advances in Therapy

Authors: Sanjay Kalra, Stephen Atkin, Antonio Cervera, Ashok Kumar Das, Ozgur Demir, Tevfik Demir, Md. Fariduddin, Khoa Tuan Vo, Bon Jeong Ku, Ajay Kumar, Zafar A. Latif, Rachid Malek, Bien J. Matawaran, Roopa Mehta, Nam Quang Tran, Araceli Panelo, Sundeep Ruder, Joel Rodriquez Saldana, Khalid A. Shaikh, Amit Shakya, Dina Shrestha, A. G. Unnikrishnan

Publisher: Springer Healthcare

share
SHARE

Abstract

Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.
Literature
1.
Garber J. The importance of titrating starting insulin regimens in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(5):14–8. CrossRefPubMed
2.
Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364–79. CrossRefPubMedPubMedCentral
3.
Nathan M, Buse J, Davidson B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203. CrossRefPubMedPubMedCentral
4.
COMUNICADO: Ryzodeg ® Significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan. http://​www.​europapress.​es/​comunicados/​internacional-00907/​noticia-comunicado-ryzodeg-significantly-reduces-the-risk-of-low-blood-sugar-in-people-with-type-diabetes-who-fast-during-ramadan-20171207094659.​html. Accessed 12 Feb 2018.
6.
Kalra S, Baruah M. Insulin degludec aspart: one-year real world experience. Indian J Endocrinol Metab. 2016;20(3):369–71. CrossRefPubMedPubMedCentral
7.
Havelund S, Ribel U, Hubalek F et al. Insulin degludec (IDeg) and insulin aspart (IAsp) can be co-formulated such that the formation of IDeg multi-hexamers and IAsp monomers is retained upon s.c. injection. In: Poster presented at ADA 2013 Chicago. 945P.
8.
Haahr H, Fita E, Heise T. A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet. 2017;56:339–54. CrossRefPubMed
9.
Brunner M, Pieber T, Korsatko S, Kojzar H, Svendsen AL, Haahr H. The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes. Drugs Aging. 2015;32:583–90. CrossRefPubMedPubMedCentral
10.
Onishi Y, Ono Y, Rabol R. Superior glycaemic control with once–daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013;15:826–32. CrossRefPubMed
11.
Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG. Treatment intensification with an insulin degludec (IDeg)/insulin aspart(IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab. 2016;18:274–80. CrossRefPubMedPubMedCentral
12.
Franek E, Haluzík M, Canecki Varžić S, et al. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with type 2 diabetes. Diabet Med. 2016;33:497–505. CrossRefPubMed
13.
Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37:2084–90. CrossRefPubMed
14.
Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). Diabet Med. 2017;34:167–73.
15.
Kaneko S, Chow F, Choi S. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or premixed insulin: a 26-week, randomised, treat to-target trial. Diabetes Res Clin Pract. 2015;107:139–47. CrossRefPubMed
16.
Kalra S, Latif A, Comlekci A, et al. Pragmatic use of insulin degludec/insulin aspart co-formulation: a multinational consensus statement. Indian J Endocr Metab. 2016;20(4):542–5. CrossRef
17.
Kalra S. Insulin degludec and insulin degludec/insulin aspart in Ramadan: a single center experience. Indian J Endocrinol Metab. 2016;20(4):564–7. CrossRefPubMedPubMedCentral
18.
American Diabetes Association. Introduction: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(1):S1–2.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions